1 Goldner, E. M., Hsu, L., Waraich, P. & Somers, J. M. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 47, 833-843, doi:10.1177/070674370204700904 (2002).
2 Correll, C. U. et al. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. J Clin Psychiatry 77, 1-24, doi:10.4088/JCP.15032su1 (2016).
3 Ng CS, Lee JY, Toh MP, Ko Y. Cost-of-illness studies of diabetes mellitus: a systematic review. Diabetes Res Clin Pract. 2014;105(2):151–163
4 Leardini G, Salaffi F, Caporali R, Canesi B, Rovati L, Montanelli R. Direct and indirect costs of osteoarthritis of the knee. Clin Exp Rheumatol. 2004;22(6):699–706.
5 Castro DM, Dillon C, Machnicki G, Allegri RF. The economic cost of Alzheimer’s disease: family or public health burden? Dement Neuropsychol. 2010;4(4):262–267.
6 Filipovic I, Walker D, Forster F, Curry AS. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1083–1090.
7 Dadoun S, Guillemin F, Lucier S, et al. Work productivity loss in early arthritis during the first 3 years of disease: a study from a French national multicenter cohort. Arthritis Care Res. 2014;66(9):1310–1318.
8 Ascher-Svanum, H. et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 67, 453-460, doi:10.4088/jcp.v67n0317 (2006).
9 Haddad, P. M., Brain, C. & Scott, J. Non-adherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 5, 43-62, doi:10.2147/PROM.S42735 (2014).
10 MacEwan, J. P. et al. Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia. J Manag Care Spec Pharm 22, 1349-1361, doi:10.18553/jmcp.2016.22.11.1349 (2016).
11 Novick, D. et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 176, 109-113, doi:10.1016/j.psychres.2009.05.004 (2010).
12 Saraceno, B. et al. Barriers to improvement of mental health services in low-income and middle-income countries. Lancet 370, 1164-1174, doi:10.1016/S0140-6736(07)61263-X (2007).
13 Kleine-Budde, K. et al. Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord 16, 337-353, doi:10.1111/bdi.12165 (2014).
14 Cooper, N. J. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 39, 28-33, doi:10.1093/rheumatology/39.1.28 (2000).
15 Greene, M. et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ 21, 127-134, doi:10.1080/13696998.2017.1379412 (2018).
16 Marcus, S. C., Zummo, J., Pettit, A. R., Stoddard, J. & Doshi, J. A. Antipsychotic Adherenceand Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. J Manag Care Spec Pharm 21, 754-768, doi:10.18553/jmcp.2015.21.9.754 (2015).
17 Tiihonen, J. et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29823 Patients With Schizophrenia. JAMA Psychiatry 74, 686-693, doi:10.1001/jamapsychiatry.2017.1322 (2017).
18 Taipale, H., Mehtala, J., Tanskanen, A. & Tiihonen, J. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up. Schizophr Bull 44, 1381-1387, doi:10.1093/schbul/sbx176 (2018)
19 West, J. C. et al. Use of depot antipsychotic medications for medication Non-adherence in schizophrenia. Schizophr Bull 34, 995-1001, doi:10.1093/schbul/sbm137 (2008)
20 Lafeuille MH, Grittner AM, Fortier J, et al. Comparison of rehospitalization rates and associated costs among patents with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Am J Health Syst Pharm.2015:72:378-389.
21 Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry.2016:77:1-24.
22 Lieberman, J. A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353, 1209-1223, doi:10.1056/NEJMoa051688 (2005).
23 Davies, L. M. & Drummond, M. F. Economics and schizophrenia: the real cost. Br J Psychiatry Suppl, 18-21 (1994).
24 Chue, P. S., Heeg, B., Buskens, E. & van Hout, B. A. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 23 Suppl 1, 62-74, doi:10.2165/00019053-200523001-00006 (2005)
25 Davies, L. M. & Drummond, M. F. Economics and schizophrenia: the real cost. Br J Psychiatry Suppl, 18-21 (1994).
26 Chue, P. S., Heeg, B., Buskens, E. & van Hout, B. A. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 23 Suppl 1, 62-74, doi:10.2165/00019053-200523001-00006 (2005)
27 Lafeuille MH, Grittner AM, Fortier J, et al. Comparison of rehospitalization rates and associated costs among patents with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Am J Health Syst Pharm.2015:72:378-389.
28 Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry.2016:77:1-24.
29 Lefebvre, P. et al. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse. Clin Ther 39, 1380-1395 e1384, doi:10.1016/j.clinthera.2017.05.356 (2017).
30 Tajima-Pozo K, de Castro Oller MJ, Lewczuk A, Montanes-Rada F. Understanding the direct and indirect costs of patients with schizophrenia. F1000Res. 2015;4:182. https://doi.org/10.12688 /f1000research.6699.2.